SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on September 12, 2023. The filing discloses the entry into a material definitive agreement and the unregistered sale of equity securities. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction (September PIPE) rather than standard periodic financial results. Key metrics from the transaction include:
- Total Consideration Raised: $549,999.29
- Common Shares Sold: 990,954 shares
- Purchase Price per Share: $0.55502
- Warrants Issued to Investors: 495,477 warrants (50% of shares sold)
- Warrant Exercise Price: $0.49252 per share
- Warrant Terms: Exercisable after six months; expire five and one-half years from issuance.
Additionally, a warrant to purchase 67,565 shares was issued to financial advisor Laidlaw & Company (UK) Ltd. as partial compensation, with identical exercise price and term conditions.
Material Changes
The primary material change is the dilution of existing shareholders due to the issuance of 990,954 new shares and 563,042 total warrants (investor and advisor combined). The filing does not provide comparative financial data (revenue, profit, or cash flow) against prior periods as this is a transaction-specific report.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond standard representations and warranties typical for such transactions. The securities were sold in reliance on exemptions from registration under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the exact number of outstanding shares post-transaction to assess dilution impact.
- Confirm the use of proceeds from the $549,999.29 capital raise as disclosed in subsequent filings.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and restrictions.
- Monitor the exercise of the 563,042 warrants issued, which could lead to further dilution starting six months after issuance.